Persephone Biosciences to Present at Chardan’s 4th Annual Metagenomics and Microbiome Medicines Summit
Persephone Biosciences Inc., a biotechnology company aiming to develop better treatment outcomes and improve disease prevention through a greater understanding of the microbiome, announced that the company will present and host 1×1 meetings with investors at Chardan’s 4th Annual Metagenomics and Microbiome Medicines Summit.
Latest Aithority Insights: Securitybridge Broadens U.S. Reach With New 1st Basis Group Partnership
“Great Debate – Is the term ‘Microbiome’ Drug Development Now Passé?”
- The company’s presentation will take place virtually on March 1, 2022, at 4:00 p.m. ET.
- Dr. Stephanie Culler, Persephone Biosciences’ co-founder and CEO, will also participate in the panel titled, “Great Debate – Is the term ‘Microbiome’ Drug Development Now Passé?” at 3:15 p.m. ET.
Browse The Complete News About Aithority: Fluree Chosen To Provide Patient-owned Verifiable, Cryptographically Protected Digital Health Records
Persephone aims to develop better treatment outcomes and improve disease prevention through a greater understanding of the microbiome. Persephone’s technology platform is based on diverse and inclusive, population-scale, observational clinical trials in conjunction with advanced multi-omics analyses and machine learning with the aim to probe the complex interaction between microbes and the immune system. Persephone develops precision immunotherapies utilizing synthetic biology and companion diagnostics for unmet needs and more equitable treatment outcomes.
Read More About Aithority News : Wind River Studio Supports Intel SoCs for Real-Time and AI-Driven Intelligent Systems for Aerospace and Defense Edge Applications
[To share your insights with us, please write to sghosh@martechseries.com]
Comments are closed.